A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

J. F. Seymour, D. W. Kim, E. Rubin, A. Haregewoin, J. Clark, P. Watson, T. Hughes, I. Dufva, J. L. Jimenez, F. X. Mahon, P. Rousselot, J. Cortes, G. Martinelli, C. Papayannidis, A. Nagler, F. J. Giles

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation. Adults with Ph+ chronic phase (CP)-, accelerated phase (AP)-or blast phase (BP)-CML, or ALL and documented BCR-ABL T315I mutation were treated with a 5-day continuous infusion of MK-0457 administered every 14 days at 40 mg/m2/h, 32 mg/m2/h or 24 mg/m2/h. Fifty-two patients (CP, n = 15; AP, n = 14; BP, n = 11; Ph+ ALL, n = 12) were treated. Overall, 8% of patients achieved major cytogenetic response; 6% achieved unconfirmed complete or partial response; 39% had no response. Two patients (CP CML) achieved complete hematologic response. No patients with advanced CML or Ph+ ALL achieved major hematologic response. The most common adverse event (AE) was neutropenia (50%). The most common grade 3/4 AEs were neutropenia (46%) and febrile neutropenia (35%). MK-0457 demonstrated minimal efficacy and only at higher, intolerable doses; lower doses were tolerated and no unexpected toxicities were observed. These data will assist in the development of future aurora kinase inhibitors and in the selection of appropriate target patient populations.

LanguageEnglish
Article numbere238
JournalBlood cancer journal
Volume4
Issue number8
DOIs
Publication statusPublished - 1 Jan 2014

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Seymour, J. F. ; Kim, D. W. ; Rubin, E. ; Haregewoin, A. ; Clark, J. ; Watson, P. ; Hughes, T. ; Dufva, I. ; Jimenez, J. L. ; Mahon, F. X. ; Rousselot, P. ; Cortes, J. ; Martinelli, G. ; Papayannidis, C. ; Nagler, A. ; Giles, F. J. / A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. In: Blood cancer journal. 2014 ; Vol. 4, No. 8.
@article{2a6eccb058af4a22815ad32bcb2dbcad,
title = "A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia",
abstract = "Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation. Adults with Ph+ chronic phase (CP)-, accelerated phase (AP)-or blast phase (BP)-CML, or ALL and documented BCR-ABL T315I mutation were treated with a 5-day continuous infusion of MK-0457 administered every 14 days at 40 mg/m2/h, 32 mg/m2/h or 24 mg/m2/h. Fifty-two patients (CP, n = 15; AP, n = 14; BP, n = 11; Ph+ ALL, n = 12) were treated. Overall, 8{\%} of patients achieved major cytogenetic response; 6{\%} achieved unconfirmed complete or partial response; 39{\%} had no response. Two patients (CP CML) achieved complete hematologic response. No patients with advanced CML or Ph+ ALL achieved major hematologic response. The most common adverse event (AE) was neutropenia (50{\%}). The most common grade 3/4 AEs were neutropenia (46{\%}) and febrile neutropenia (35{\%}). MK-0457 demonstrated minimal efficacy and only at higher, intolerable doses; lower doses were tolerated and no unexpected toxicities were observed. These data will assist in the development of future aurora kinase inhibitors and in the selection of appropriate target patient populations.",
author = "Seymour, {J. F.} and Kim, {D. W.} and E. Rubin and A. Haregewoin and J. Clark and P. Watson and T. Hughes and I. Dufva and Jimenez, {J. L.} and Mahon, {F. X.} and P. Rousselot and J. Cortes and G. Martinelli and C. Papayannidis and A. Nagler and Giles, {F. J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/bcj.2014.60",
language = "English",
volume = "4",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "8",

}

Seymour, JF, Kim, DW, Rubin, E, Haregewoin, A, Clark, J, Watson, P, Hughes, T, Dufva, I, Jimenez, JL, Mahon, FX, Rousselot, P, Cortes, J, Martinelli, G, Papayannidis, C, Nagler, A & Giles, FJ 2014, 'A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia', Blood cancer journal, vol. 4, no. 8, e238. https://doi.org/10.1038/bcj.2014.60

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. / Seymour, J. F.; Kim, D. W.; Rubin, E.; Haregewoin, A.; Clark, J.; Watson, P.; Hughes, T.; Dufva, I.; Jimenez, J. L.; Mahon, F. X.; Rousselot, P.; Cortes, J.; Martinelli, G.; Papayannidis, C.; Nagler, A.; Giles, F. J.

In: Blood cancer journal, Vol. 4, No. 8, e238, 01.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

AU - Seymour, J. F.

AU - Kim, D. W.

AU - Rubin, E.

AU - Haregewoin, A.

AU - Clark, J.

AU - Watson, P.

AU - Hughes, T.

AU - Dufva, I.

AU - Jimenez, J. L.

AU - Mahon, F. X.

AU - Rousselot, P.

AU - Cortes, J.

AU - Martinelli, G.

AU - Papayannidis, C.

AU - Nagler, A.

AU - Giles, F. J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation. Adults with Ph+ chronic phase (CP)-, accelerated phase (AP)-or blast phase (BP)-CML, or ALL and documented BCR-ABL T315I mutation were treated with a 5-day continuous infusion of MK-0457 administered every 14 days at 40 mg/m2/h, 32 mg/m2/h or 24 mg/m2/h. Fifty-two patients (CP, n = 15; AP, n = 14; BP, n = 11; Ph+ ALL, n = 12) were treated. Overall, 8% of patients achieved major cytogenetic response; 6% achieved unconfirmed complete or partial response; 39% had no response. Two patients (CP CML) achieved complete hematologic response. No patients with advanced CML or Ph+ ALL achieved major hematologic response. The most common adverse event (AE) was neutropenia (50%). The most common grade 3/4 AEs were neutropenia (46%) and febrile neutropenia (35%). MK-0457 demonstrated minimal efficacy and only at higher, intolerable doses; lower doses were tolerated and no unexpected toxicities were observed. These data will assist in the development of future aurora kinase inhibitors and in the selection of appropriate target patient populations.

AB - Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation. Adults with Ph+ chronic phase (CP)-, accelerated phase (AP)-or blast phase (BP)-CML, or ALL and documented BCR-ABL T315I mutation were treated with a 5-day continuous infusion of MK-0457 administered every 14 days at 40 mg/m2/h, 32 mg/m2/h or 24 mg/m2/h. Fifty-two patients (CP, n = 15; AP, n = 14; BP, n = 11; Ph+ ALL, n = 12) were treated. Overall, 8% of patients achieved major cytogenetic response; 6% achieved unconfirmed complete or partial response; 39% had no response. Two patients (CP CML) achieved complete hematologic response. No patients with advanced CML or Ph+ ALL achieved major hematologic response. The most common adverse event (AE) was neutropenia (50%). The most common grade 3/4 AEs were neutropenia (46%) and febrile neutropenia (35%). MK-0457 demonstrated minimal efficacy and only at higher, intolerable doses; lower doses were tolerated and no unexpected toxicities were observed. These data will assist in the development of future aurora kinase inhibitors and in the selection of appropriate target patient populations.

UR - http://www.scopus.com/inward/record.url?scp=84906878307&partnerID=8YFLogxK

U2 - 10.1038/bcj.2014.60

DO - 10.1038/bcj.2014.60

M3 - Article

VL - 4

JO - Blood Cancer Journal

T2 - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 8

M1 - e238

ER -